{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T19:01:42Z","timestamp":1787166102873,"version":"build-2736575974"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T00:00:00Z","timestamp":1751414400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T00:00:00Z","timestamp":1751414400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Oral Health"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>MRONJ (Medication-Related Osteonecrosis of the Jaw) refers to a condition characterized by osteonecrosis of the jawbone associated with the use of certain medications. One of the most common causes of MRONJ is bisphosphonates, which are frequently used today to treat osteoporosis, metabolic bone diseases, and the skeletal effects of malignancies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>The aim of this study is to assess the awareness and approaches of medical doctors who prescribe bisphosphonate group drugs regarding MRONJ.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method<\/jats:title>\n                    <jats:p>A total of 125 physicians specializing in the departments of oncology, orthopedics and traumatology, physical medicine and rehabilitation, and obstetrics and gynecology participated in our study. The participants completed questionnaire forms consisting of 15 questions related to MRONJ, and the results were analyzed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The specialists who participated in the study were found to prescribe zoledronate and alendronate more frequently than other antiresorptive medications. Over the past year, when examining the frequency of encountering patients with MRONJ, 56% of physicians had not encountered any cases, while 44% had encountered between one and four cases. The group that most frequently requested consultations from physicians regarding bisphosphonates was identified as dentists, with a rate of 50.4%, followed by oral and maxillofacial surgeons at 36.8%. The specialists who participated in the study reported that when they encounter patients with osteonecrosis, 39.2% most frequently referred them to oral and maxillofacial surgery.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>To enhance awareness of MRONJ, a multidisciplinary approach should be adopted between medical and dental disciplines, and a well-coordinated consultation system should be established. This will ensure that patients undergo dental examinations and complete necessary interventional dental procedures before commencing antiresorptive drug therapy. Furthermore, implementing educational strategies such as academic publications, training seminars, and symposia is of great importance to increase the level of awareness on this issue.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12903-025-06490-5","type":"journal-article","created":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T03:01:44Z","timestamp":1751425304000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Awareness and Attitude Towards MRONJ Among Physicians Prescribing Antiresorptive Drugs: A Cross-Sectional Study"],"prefix":"10.1186","volume":"25","author":[{"given":"Murat","family":"Mutlu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serpil","family":"Altundo\u011fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-0681-0648","authenticated-orcid":false,"given":"\u00d6mer Faruk","family":"Kocamaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,2]]},"reference":[{"issue":"10","key":"6490_CR1","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1016\/j.joms.2014.04.031","volume":"72","author":"SL Ruggiero","year":"2014","unstructured":"Ruggiero SL, Dodson TB, Fantasia J, Goodday R, Aghaloo T, Mehrotra B, O\u2019Ryan F. American Association of Oral and Maxillofacial Surgeons Position Paper on Medication-Related Osteonecrosis of the Jaw-2014 Update. J Oral Maxillofac Surg. 2014;72(10):1938\u201356.","journal-title":"J Oral Maxillofac Surg"},{"issue":"4","key":"6490_CR2","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.coms.2007.07.003","volume":"19","author":"Y Sawatari","year":"2007","unstructured":"Sawatari Y, Marx RE. Bisphosphonates and Bisphosphonate Induced Osteonecrosis. Oral Maxillofac Surg Clin North Am. 2007;19(4):487\u201398.","journal-title":"Oral Maxillofac Surg Clin North Am"},{"issue":"1","key":"6490_CR3","doi-asserted-by":"publisher","first-page":"5","DOI":"10.4103\/njms.NJMS_236_20","volume":"13","author":"H Bansal","year":"2022","unstructured":"Bansal H. Medication-related osteonecrosis of the jaw: An update. Natl J Maxillofac Surg. 2022;13(1):5\u201310.","journal-title":"Natl J Maxillofac Surg"},{"issue":"1","key":"6490_CR4","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s40729-021-00323-0","volume":"7","author":"M Kawahara","year":"2021","unstructured":"Kawahara M, Kuroshima S, Sawase T. Clinical considerations for medication-related osteonecrosis of the jaw: a comprehensive literature review. Int J Implant Dent. 2021;7(1):47.","journal-title":"Int J Implant Dent"},{"issue":"9","key":"6490_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsps.2023.101707","volume":"31","author":"S Aljohani","year":"2023","unstructured":"Aljohani S. Awareness, perceptions and attitudes toward medication-related osteonecrosis of the jaw among physicians who treat osteoporsis. Saudi Pharm J. 2023;31(9): 101707.","journal-title":"Saudi Pharm J"},{"issue":"3","key":"6490_CR6","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.bone.2007.04.196","volume":"41","author":"IR Reid","year":"2007","unstructured":"Reid IR, Bolland MJ, Grey AB. Is bisphosphonate-associated osteonecrosis of the jaw caused by soft tissue toxicity? Bone. 2007;41(3):318\u201320.","journal-title":"Bone"},{"key":"6490_CR7","doi-asserted-by":"crossref","unstructured":"Advisory Task Force on Bisphosphonate-Related Ostenonecrosis of the Jaws. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. Journal of Oral and Maxillofacial Surgery\u202f: Official Journal of the American Association of Oral and Maxillofacial Surgeons. 2007:65(3):369\u201376.","DOI":"10.1016\/j.joms.2006.11.003"},{"issue":"10","key":"6490_CR8","doi-asserted-by":"publisher","DOI":"10.1002\/jbm4.10800","volume":"7","author":"H Wadhwa","year":"2023","unstructured":"Wadhwa H, Wu YJ, Lee SJ, Zygourakis CC. Anabolic and Antiresorptive Osteoporosis Treatment: Trends, Cost, and Sequence in a Commercially Insured Population,2003\u20132021. JBMR Plus. 2023;7(10): e10800.","journal-title":"JBMR Plus"},{"issue":"6","key":"6490_CR9","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1007\/s00223-015-0045-y","volume":"97","author":"A Taguchi","year":"2015","unstructured":"Taguchi A, Shiraki M, Tsukiyama M, Miyazaki T, Satoshi S, Ohta H, Nakamura T, Orimo H. Impact of Osteonecrosis of the Jaw on Osteoporosis Treatment in Japan: Results of a Questionnaire-Based Survey by the Adequate Treatment of Osteoporosis (A-TOP) Research Group. Calcif Tissue Int. 2015;97(6):542\u201350.","journal-title":"Calcif Tissue Int"},{"issue":"1","key":"6490_CR10","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1177\/0748175613513808","volume":"47","author":"C Ayre","year":"2014","unstructured":"Ayre C, Scally AJ. Critical values for Lawshe\u2019s content validity ratio: revisiting the original methods of calculation. Meas Eval Couns Dev. 2014;47(1):79\u201386.","journal-title":"Meas Eval Couns Dev"},{"issue":"6","key":"6490_CR11","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1111\/j.1601-0825.2009.01568.x","volume":"15","author":"M Sarasquete","year":"2009","unstructured":"Sarasquete M, Gonz\u00e1lez M, San Miguel J, Garc\u00eda-Sanz R. Bisphosphonate-related osteonecrosis: genetic and acquired risk factors. Oral Dis. 2009;15(6):382\u20137.","journal-title":"Oral Dis"},{"key":"6490_CR12","unstructured":"Senturk MF, Cimen E, Tuzuner Oncul AM, Cambazoglu M. Oncologists awareness about bisphosphonate related osteonecrosis of the jaws. JPMA. The Journal of the Pakistan Medical Association. 2016:66(7):880\u201383."},{"key":"6490_CR13","volume-title":"Medikal Onkoloji Uzmanlar\u0131n\u0131n Medikal \u0130la\u00e7larla \u0130li\u015fkili \u00c7ene Osteonekrozu (MRONJ)\u2019na Dair Tutumlar\u0131n\u0131n De\u011felendirilmesi [dissertation]","author":"S Karc\u0131","year":"2018","unstructured":"Karc\u0131 S. Medikal Onkoloji Uzmanlar\u0131n\u0131n Medikal \u0130la\u00e7larla \u0130li\u015fkili \u00c7ene Osteonekrozu (MRONJ)\u2019na Dair Tutumlar\u0131n\u0131n De\u011felendirilmesi [dissertation]. Konya: Sel\u00e7uk University; 2018."},{"issue":"1","key":"6490_CR14","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s12903-016-0290-0","volume":"16","author":"JW Kim","year":"2016","unstructured":"Kim JW, Jeong SR, Kim SJ, Kim Y. Perceptions of medical doctors on bisphosphonate-related osteonecrosis of the jaw. BMC Oral Health. 2016;16(1):92.","journal-title":"BMC Oral Health"},{"issue":"10","key":"6490_CR15","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.14219\/jada.archive.2009.0049","volume":"140","author":"PP Sedghizadeh","year":"2009","unstructured":"Sedghizadeh PP, Kumar SKS, Gorur A, Schaudinn C, Shuler CF, Costerton JW. Microbial Biofilms in Osteomyelitis of the Jaw and Osteonecrosis of the Jaw Secondary to Bisphosphonate Therapy. J Am Dent Assoc. 2009;140(10):1259\u201365.","journal-title":"J Am Dent Assoc"},{"issue":"8","key":"6490_CR16","first-page":"830","volume":"32","author":"MA Al-Mohaya","year":"2011","unstructured":"Al-Mohaya MA, Al-Khashan HI, Mishriky AM, Al-Otaibi LM. Physicians\u2019 awareness of bisphosphonates-related osteonecrosis of the jaw. Saudi Med J. 2011;32(8):830\u20135.","journal-title":"Saudi Med J"},{"issue":"9","key":"6490_CR17","doi-asserted-by":"publisher","first-page":"2825","DOI":"10.1007\/s00520-015-2649-1","volume":"23","author":"L El Osta","year":"2015","unstructured":"El Osta L, El Osta B, Lakiss S, Hennequin M, El Osta N. Bisphosphonate-related osteonecrosis of the jaw: awareness and level of knowledge of Lebanese physicians. Supportive Care in Cancer\u202f: Official Journal of the Multinational Association of Supportive Care in Cancer. 2015;23(9):2825\u201331.","journal-title":"Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer"},{"issue":"2","key":"6490_CR18","doi-asserted-by":"publisher","first-page":"168","DOI":"10.5336\/dentalsci.2020-75321","volume":"27","author":"G \u015eenol","year":"2021","unstructured":"\u015eenol G, G\u00fcldiken IN, Suzen M, Ko\u00e7yi\u011fit H, Delilba\u015fi \u00c7. MRONJ approach of medical doctors who prescribing antiresorptive drug. Turkiye Klinikleri Journal of Dental Sciences. 2021;27(2):168\u201377.","journal-title":"Turkiye Klinikleri Journal of Dental Sciences"},{"issue":"4","key":"6490_CR19","first-page":"367","volume":"124","author":"AAOM clinical practice statement","year":"2017","unstructured":"AAOM clinical practice statement. Oral Surgery, Oral Medicine, Oral Pathology and Oral. Radiology. 2017;124(4):367\u20138.","journal-title":"Radiology"},{"issue":"1","key":"6490_CR20","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s13167-019-0160-3","volume":"10","author":"M Salgueiro","year":"2019","unstructured":"Salgueiro M, Stribos M, Zhang LF, Stevens M, Awad ME, Elsalanty M. Value of pre-operative CTX serum levels in the prediction of medication-related osteonecrosis of the jaw (MRONJ): a retrospective clinical study. EPMA J. 2019;10(1):21\u20139.","journal-title":"EPMA J"},{"issue":"3","key":"6490_CR21","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1111\/j.1600-0714.2011.01091.x","volume":"41","author":"P Vescovi","year":"2012","unstructured":"Vescovi P, Merigo E, Meleti M, Manfredi M, Guidotti R, Nammour S. Bisphosphonates-related osteonecrosis of the jaws: a concise review of the literature and a report of a single-centre experience with 151 patients. J Oral Pathol Med. 2012;41(3):214\u201321.","journal-title":"J Oral Pathol Med"}],"container-title":["BMC Oral Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12903-025-06490-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12903-025-06490-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12903-025-06490-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T03:01:48Z","timestamp":1751425308000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcoralhealth.biomedcentral.com\/articles\/10.1186\/s12903-025-06490-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,2]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["6490"],"URL":"https:\/\/doi.org\/10.1186\/s12903-025-06490-5","relation":{},"ISSN":["1472-6831"],"issn-type":[{"value":"1472-6831","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,2]]},"assertion":[{"value":"12 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Ankara University Health Sciences Sub-Ethics Committee has approved the research protocol (decision date. 29\/01\/2024,\u00a0 decision number. 02\/05). The purpose and content of the study were explained to the participants of the study. Those who agreed to participate were asked to sign an informed consent form and complete the questionnaire. The study has been conducted in accordance with the Declaration\u00a0 of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"985"}}